Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (757)	12/10/1998 6:57:00 PM
From: lrrp	Read Replies (2) \| Respond to of 2539

check the references on Grateful med re:cox 2 inhibitors--search medline --here is one of the published refs available to all::::Hope this helps National Library of Medicine: IGM Full Record Screen [Help] [show_loansome] [Log off IGM] [Next Record] [infosearch_1] [Return to Results] [Return to Search Screen] [Previous Record] ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- [FR_9751091] TITLE: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo- controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. AUTHORS: Simon LS; Lanza FL; Lipsky PE; Hubbard RC; Talwalker S; Schwartz BD; Isakson PC; Geis GS AUTHOR Beth Israel Deaconess Medical Center, Harvard Medical AFFILIATION: School, Boston, Massachusetts 02215, USA. SOURCE: Arthritis Rheum 1998 Sep;41(9):1591-602 CITATION IDS: PMID: 9751091 UI: 98421711 ABSTRACT: OBJECTIVE: To investigate the efficacy and safety of SC-58635 (celecoxib), an antiinflammatory and analgesic agent that acts by selective cyclooxygenase 2 (COX-2) inhibition and is not expected to cause the typical gastrointestinal (GI), renal, and platelet-related side effects associated with inhibition of the COX-1 enzyme. METHODS: Four phase II trials were performed: a 2-week osteoarthritis efficacy trial, a 4-week rheumatoid arthritis efficacy trial, a 1-week endoscopic study of GI mucosal effects, and a 1-week study of effects on platelet function. RESULTS: The 2 arthritis trials identified SC- 58635 dosage levels that were consistently effective in treating the signs and symptoms of arthritis and were distinguished from placebo on standard arthritis scales. In the upper GI endoscopy study, 19% of subjects receiving naproxen (6 of 32) developed gastric ulcers, whereas no ulcers occurred in subjects receiving SC-58635 or placebo. The study of platelet effects revealed no meaningful effect of SC-58635 on platelet aggregation or thromboxane B2 levels, whereas aspirin caused significant decreases in 2 of 3 platelet aggregation measures and thromboxane B2 levels. In all 4 trials, SC-58635 was well tolerated, with a safety profile similar to that of placebo. CONCLUSION: SC-58635 achieves analgesic and antiinflammatory efficacy in arthritis through selective COX-2 inhibition, without showing any evidence of 2 of the toxic effects of COX-1 inhibition associated with nonsteroidal antiinflammatory drugs. MAIN MESH Arthritis, Rheumatoid/drug therapy HEADINGS: Cyclooxygenase Inhibitors/therapeutic use Osteoarthritis/drug therapy Sulfonamides/therapeutic use ADDITIONAL Adult MESH HEADINGS: Aged Aged, 80 and over Aspirin/therapeutic use Cyclooxygenase Inhibitors/adverse effects Endoscopy Female Human Knee Joint/drug effects Knee Joint/pathology Male Middle Age Naproxen/adverse effects Platelet Aggregation/drug effects Platelet Aggregation Inhibitors/therapeutic use Safety Severity of Illness Index Stomach Ulcer/chemically induced Stomach Ulcer/pathology Sulfonamides/adverse effects Support, Non-U.S. Gov't Thromboxane B2/blood Treatment Outcome PUBLICATION CLINICAL TRIAL TYPES: CLINICAL TRIAL, PHASE II JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL CAS REGISTRY 0 (Cyclooxygenase Inhibitors) NUMBERS: 0 (Platelet Aggregation Inhibitors) 0 (Sulfonamides) 184007-95-2 (celecoxib) 22204-53-1 (Naproxen) 50-78-2 (Aspirin) 54397-85-2 (Thromboxane B2) LANGUAGES: Eng --------------------------------------------------------------------------- [Help] [show_loansome] [Log off IGM] [Next Record] [infosearch_1] [Return to Results] [Return to Search Screen] [Previous Record]